Abstract 221P
Background
The gold standard treatment for the non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guerin (BCG). the instillation of BCG induces an inflammatory response followed by cytokines upregulation and downregulation with a clinical outcome. In this we are targeting the IL1-alpha and TNF-alpha genes and study their genetic polymorphism to elucidate their role in BCG response and tumor recurrence in NMIBC patients.
Methods
The blood samples collected from histopathologically confirmed 224 NMIBC patients from August 2020 to December 2022. The 124 patients were grouped as BCG nonresponsive (BCG-NR) and 100 patients were grouped under BCG-responsive (BCG-R). The classification of group based on the BCG response followed by SWOG protocol. Recurrence/progression of tumor after 6 months consider for the BCG-NR followed by cystoscopy. In contrast patients with no sign of recurrence and progression after 12 months of BCG therapy consider as BCG-R. The DNA was isolated for the genotypic analysis of IL1A -889 C/T-(rs1800587) and TNFA-1031 T/C (rs1799964), in both groups using Taq-Man Probe-based real-time polymerase chain reactions.
Results
In this study, IL1A -889 C, and TNFA, 1031's C allele frequency, were significantly higher in BCG-NR (P <.05). The IL-1 alpha-889 C/T (CC/CT+TT) and TNFA -1031 T/C (TT/TC+CC) genotype expression were shown to be significantly associated with BCG-NR and tumour recurrence (CC/CT+TT; P=.025, TT/TC+CC; P =0.045) as compared to BCG-R in NMIBC.
Conclusions
The genetic polymorphism of the cytokines IL1A -889 C/T (rs1800587) and TNFA-1031 (rs1799964) T/C is significantly susceptible to the recurrence of tumor, BCG response and lead the way for early therapeutic response in NMIBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract